Safety and efficacy analyses across age and body mass index subgroups in East Asian participants with type 2 diabetes in the phase 3 tirzepatide studies (SURPASS program).
Arihiro KiyosueJulia P DunnXuewei CuiAna HickeyTetsuaki HiraseTakeshi ImaokaRobert J HeinePublished in: Diabetes, obesity & metabolism (2022)
This post-hoc analysis showed that once weekly tirzepatide had a similar safety and efficacy profile across BMI and age subgroups in East Asian participants. This article is protected by copyright. All rights reserved.